Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries

This book gives an expert view of how the project management approach can be taken forward by the pharmaceutical industry over the next decade. The book integrates portfolio, program, and project management processes as fundamentals for effective and efficient drug product development.

Informationen zum Autor PETE HARPUM is a Director of Harpum Consulting and has been consulting on Portfolio, Program, and Project Management (P3M) for some ten years. He chairs and contributes to many conferences and symposiums on P3M. Mr. Harpum's other activities include postgraduate lecturing and research on P3M for three world-class universities, and supporting the Association for Project Management, Project Management Institute, and the Drug Information Association in various ways. Klappentext The expansive, all-in-one guide tosuccessful pharmaceutical project managementTo improve the ways they currently manage projects and programs, pharmaceutical and biotechnology companies need reliable stewardship to direct future strategies. Unlike other industry sectors, they have yet to fully embrace the effective integrated processes of Portfolio, Program, and Project Management, otherwise referred to as P3M, to position themselves favorably in meeting challenges unique to the drug development business.Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries illustrates how high-quality program and project management is crucial for drug companies to remain competitive, to deliver good returns to investors, and ultimately to bring novel personalized medicine to patients with: A combination of theoretical insights and pragmatic examples from professionals who are all working in the industry Case studies with very detailed, real-life examples of how the management of drug development is actually done Answers the pharmaceutical industry needs to streamline and make the drug development process more efficient The full spectrum of management processes needed from the operational-ization of corporate strategy by portfolio management processes through to practical project control processesCarefully divided into three main sections to cover topics such as the impact of organizational size on P3M; planning and control; and reducing product safety risk, this informative reference is structured to align both novices and professionals in drug program management with success in the wake of emerging trends. Zusammenfassung This book describes the way that pharmaceutical projects and programs are currently managed, and offers views from many highly experienced practitioners from within the industry on future directions for drug program management. The book integrates portfolio, program, and project management processes as fundamental for effective and efficient drug product development. Contributing expert authors provide their view of how the projectization approach can be taken forward by the drug industry over the coming years. Inhaltsverzeichnis Preface ix Acknowledgments xi About the Authors xiii Part One The Life Science Industry Context for Portfolio, Program, and Project Management 1. A Review of Project Management in Life Science Industry Sectors 3 Thomas R. Dunson 2. The Impact of Organizational Size on Drug Project Management 21 Eric Morfin 3. Drug Development in Biotechnology and How We Can Do It Better 33 Susan Linna Part Two The Portfolio, Program, and Project Management Approaches and Processes 4. An Overview of the Organization and Processes of Portfolio, Program, and Project Management 53 Pete Harpum 5. Portfolio Management in the Pharmaceutical Industry: Balancing Corporate Need with the Reality of Delivering Products to the Market 59 John Bennett 6. Program Management in Drug Development 85 Pauline Stewart-Long 7. Project Control 101 Martin Powell 8. Managing Uncertainty in Drug Projects 135 Pete Harpum and Thomas R. Dunson 9. Managing Drug Safety Risk 155 Thomas R. Dunson and Eric Morfin 10. Developing Program Strat...

Auteur

PETE HARPUM is a Director of Harpum Consulting and has been consulting on Portfolio, Program, and Project Management (P3M) for some ten years. He chairs and contributes to many conferences and symposiums on P3M. Mr. Harpum's other activities include postgraduate lecturing and research on P3M for three world-class universities, and supporting the Association for Project Management, Project Management Institute, and the Drug Information Association in various ways.

Texte du rabat
The expansive, all-in-one guide to successful pharmaceutical project management To improve the ways they currently manage projects and programs, pharmaceutical and biotechnology companies need reliable stewardship to direct future strategies. Unlike other industry sectors, they have yet to fully embrace the effective integrated processes of Portfolio, Program, and Project Management, otherwise referred to as P3M, to position themselves favorably in meeting challenges unique to the drug development business. Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries illustrates how high-quality program and project management is crucial for drug companies to remain competitive, to deliver good returns to investors, and ultimately to bring novel personalized medicine to patients with: A combination of theoretical insights and pragmatic examples from professionals who are all working in the industry Case studies with very detailed, real-life examples of how the management of drug development is actually done Answers the pharmaceutical industry needs to streamline and make the drug development process more efficient The full spectrum of management processes needed from the operational-ization of corporate strategy by portfolio management processes through to practical project control processes Carefully divided into three main sections to cover topics such as the impact of organizational size on P3M; planning and control; and reducing product safety risk, this informative reference is structured to align both novices and professionals in drug program management with success in the wake of emerging trends.

Résumé
This book describes the way that pharmaceutical projects and programs are currently managed, and offers views from many highly experienced practitioners from within the industry on future directions for drug program management. The book integrates portfolio, program, and project management processes as fundamental for effective and efficient drug product development. Contributing expert authors provide their view of how the projectization approach can be taken forward by the drug industry over the coming years.

Contenu

Preface ix

Acknowledgments xi

About the Authors xiii

Part One The Life Science Industry Context for Portfolio, Program, and Project Management

1. A Review of Project Management in Life Science Industry Sectors 3
   Thomas R. Dunson

2. The Impact of Organizational Size on Drug Project Management 21
   Eric Morfin

3. Drug Development in Biotechnology and How We Can Do It Better 33
   Susan Linna

Part Two The Portfolio, Program, and Project Management Approaches and Processes

4. An Overview of the Organization and Processes of Portfolio, Program, and Project Management 53
   Pete Harpum

5. Portfolio Management in the Pharmaceutical Industry: Balancing Corporate Need with the Reality of Delivering Products to the Market 59
   John Bennett

6. Program Management in Drug Development 85
   Pauline Stewart-Long

7. Project Control 101
   Martin Powell

8. Managing Uncertainty in Drug Projects 135
   Pete Harpum and Thomas R. Dunson

9. Managing Drug Safety Risk 155
   Thomas R. Dunson and Eric Morfin

10. Developing Program Strategy 175
    Pete Harpum

11. Developing Products with "Added Value" 197
    Trevor J. Brown and Stephen Allport

**Part Three…